Key result
The HeartMate 3 fully magnetically levitated pump was associated with near-elimination of pump thrombosis, reduced strokes, and lower mucosal bleeding rates in patients with refractory heart failure.
Design
Review
Authors
Loading...
Continuous-flow LVADs improved durability and reduced size versus pulsatile predecessors; leaves open optimal pulsatility targets in current devices.
The evolution of LVAD technology to fully magnetically levitated continuous flow pumps has significantly improved hemocompatibility by reducing pump thrombosis and strokes, though challenges like right heart failure and infections remain.
Sidhu et al. (2019) conducted a review in Refractory heart failure. Left ventricular assist devices (HeartMate 3) vs. Early generation LVADs (HeartMate II, HVAD) was evaluated. The HeartMate 3 fully magnetically levitated pump was associated with near-elimination of pump thrombosis, reduced strokes, and lower mucosal bleeding rates in patients with refractory heart failure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: